AbbVie updates 2023 EPS guidance to include $66M acquired IPR&D expense

AbbVie Inc.

2023-Q3 EPS reported $2.26 revenue$40,017,000,000

Q3 2023 acquired IPR&D & milestones expense of $66M pre-tax; reduces diluted EPS by $0.04.
Updated Q3 2023 adjusted diluted EPS guidance: $2.76 - $2.86 (previously $2.80 - $2.90).
Full-year 2023 adjusted diluted EPS guidance: $10.86 - $11.06 (previously $10.90 - $11.10).
Prior guidance excluded Q3 2023 IPR&D expense; company does not forecast such expenses.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

AbbVie Inc. updated its the third quarter of 2023 guidance (reaffirmed).

Period: the third quarter of 2023
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

Reported GAAP earnings and adjusted non-GAAP earnings for the third quarter of 2023 are expected to include acquired IPR&D and milestones expense of $66 million on a pre-tax basis, representing an unfavorable impact of $0.04 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended September 30, 2023 have not been finalized and are subject to our financial statement closing procedures.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

AbbVie Inc. filing history →

Source: SEC EDGAR

accession 0001551152-23-000036

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.